Outlook Therapeutics (OTLK) Q4 2025 earnings summary

Executive summary

• Fiscal 2025 net loss attributable to common stockholders was $62.4 million, or $1.79 per share, on $1.4 million in revenue, compared to a $75.4 million net loss and no revenue in the prior year.

• Initial commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK began in June 2025, with growing account and clinician adoption into early fiscal 2026.

• Awaiting FDA decision for U.S. approval of ONS-5010/LYTENAVA™, with a PDUFA goal date of December 31, 2025.

Financial highlights

• Revenue for fiscal 2025 was $1.4 million, reflecting first sales in Germany and the UK; no revenue was reported in fiscal 2024.

• Net loss improved to $62.4 million from $75.4 million year-over-year.

• Gross profit was negatively impacted by increased reserves for short-dated inventory in the UK.

• R&D expenses decreased significantly due to completion of the NORSE Eight clinical trial, partially offset by higher SG&A expenses for the European launch.

• Cash and cash equivalents at September 30, 2025, were $8.1 million, not including $14.9 million in net proceeds from an at-the-market offering after year-end.

Outlook and guidance

• Preparing for potential U.S. commercial launch pending FDA approval, with ongoing expansion efforts in Europe, including Austria and the Netherlands.

• LYTENAVA™ accepted into the UK tender framework in December 2025 and a real-world data study initiated in Germany.

• Continued focus on expanding market access and pricing at national and sub-national levels in Europe.